Search results
-
Hartford Financial Services Group, Inc.
Sihler, William W.; Green, RickCase DARDEN-F-1678-EFinanceThe senior managers of the Hartford have been challenged by an activist investor (John Paulson) to alter the company's strategy as a way to enhance shareholder value - the company's market price not being revealed from its 2008 fall. Management must decide how to respond.Starting at €8.20
-
J&L Railroad: The Board Meeting
Eades, Kenneth M.; Lehman, Jeannine; Green, RickCase DARDEN-F-1605-EFinanceThis short case could be handed out at the end of class discussion on “J&L Railroad” [UVA-F-1053] in preparation for the following class, or if students are more experienced with hedging and option pricing, the instructor may choose to cover both cases in a single class period. It is the companion case to “J&L Railroad" [UVA-F-1053], and presents more technical issues regarding the hedging problem by requiring students to understand option-pricin...Starting at €8.20
-
Research Affiliates
Evans, Richard B.; Green, RickCase DARDEN-F-1662-EFinanceTowers Watson (TW) has always conducted its own research into alternative approaches to market cap investing. A senior investment consultant with TW, impressed by a recent presentation by the CIO of Research Affiliates (RA) about an innovative investing concept called the “Fundamental Index methodology,” thinks it might be an important innovation in applying nonmarket cap approaches. But he has some concerns about the approach and whether or not ...Starting at €8.20
-
Catalyst Health Solutions: A Script for Success?
Harris, Robert S.; Green, RickCase DARDEN-F-1666-EFinanceIn February 2011, David Blair, CEO of Catalyst Health Solutions, was considering another acquisition. Catalyst was already the fastest-growing pharmacy benefit management company in the United States, and Blair had his eye on a subsidiary of Walgreen Co., the second-largest retail drugstore chain in the country. Walgreen Co. was focusing its corporate strategy on the retail business and had just purchased 258 Duane Reade pharmacies in New York fo...Starting at €8.20
-
The Financial Regulatory Environment
Li, Wei; Green, RickTechnical Note DARDEN-GEM-0103-EEconomicsThe financial regulatory environment in the United States covers the insurance, banking, and securities industries. This note summarizes the regulation of all three as of July 31, 2010. This compact technical note is intended to provide students with a summary of U.S. financial regulatory history. It traces regulatory agencies and the most relevant congressional acts from 1863 to 2010. Its original intent was to be used as background for the "The...Starting at €8.20
-
SEC versus Goldman Sachs (A) and (B) - Teaching Note
Li, Wei; Green, RickTeaching Note DARDEN-GEM-0101TN-EEconomicsTeaching note for product GEM-0101Starting at €0.00
-
Monsanto Company
Lipson, Marc L.; Green, RickCase DARDEN-F-1597-EFinanceMonsanto is facing an uncertain near-term financial outlook, and this case challenges students to generate an operating forecast (income statement and balance sheet operating accounts). The case naturally lends itself to sensitivity analysis related to sales growth assumptions. Suitable for MBA and undergraduate learners, it covers the basics of forecasting without introducing the complexities associated with financing. A teaching note is availab...Starting at €8.20
-
Genzyme and Relational Investors: Science and Business Collide?
Eades, Kenneth M.; Matos, Pedro; Green, RickCase DARDEN-F-1660-EFinanceThe chairman and CEO of the Genzyme Corporation, one of the country’s top five biotechnology firms, has received a phone call requesting a meeting with the cofounder and principal of a large activist investment fund that now has a 2.6% stake in his company. Before meeting with him, the CEO is aware that he needs a strategy for dealing with this “activist” investor with a track record of forcing out CEOs.Starting at €8.20
-
SEC versus Goldman Sachs (A)
Li, Wei; Green, RickCase DARDEN-GEM-0101-EEconomicsIn April 2010, the SEC brought fraud charges against Goldman Sachs for its structuring and marketing of Abacus 2007-AC1, a complex mortgage-related security. Less than two years after the onset of the great financial crisis, and in the midst of political posturing to shape agendas for the financial reform, the case discusses the market reaction to the lawsuit and the dilemma facing Lloyd Blankfein, Goldman’s CEO. The deal structure is analyzed in...Starting at €8.20
-
SEC versus Goldman Sachs (B): The Settlement-Everybody Wins, Except Fabrice Tourre
Li, Wei; Green, RickCase DARDEN-GEM-0102-EEconomicsOn July 15, 2010, the U.S. Senate obtained the 60 votes needed to pass the Dodd-Frank Wall Street Reform and Consumer Protection Act. On the same day, the SEC reached a $550 million settlement with Goldman Sachs relating to its April 16 lawsuit by dropping its fraud charges. Supporters of both sides claimed the settlement was a victory. This short case is the epilogue to "The SEC vs. Goldman Sachs" (UVA-GEM-0101).Starting at €5.74